SYRE Spyre Therapeutics reports narrower Q4 2025 pershare loss than consensus forecasts with shares edging higher in todays trading NAMI Jinxin management outlines targeted AI service investments to support next phase of operational growth XOSWW Xos Inc quarterly earnings metrics are not yet public as investors await 2024 expansion plan updates